Author

Shuizi Ding

Second Xiangya Hospital of Central South UniversityORCID 0000-0002-3587-0482Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Molecular Biology· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Organism:human· 1 Organism:rat· 1

Frequent Co-Authors

Farida AhangariiD· 2 shared Maurizio ChioccioliiD· 2 shared Naftali KaminskiiD· 2 shared Anna BackmarkiD· 1 shared Benjamin P. Readhead· 1 shared Björn Magnusson· 1 shared Brent Dickinson· 1 shared Carly MeadoriD· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Farida AhangariORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A lung targeted miR-29 Mimic as a Therapy for Pulmonary Fibrosis

Maurizio Chioccioli, Subhadeep Roy, Rachel Newell, Linda A. Pestano, Brent Dickinson, Kevin M. Rigby, Jose D. Herazo‐Maya, Gisli R. Jenkins, Steward Ian, Gauri Saini, Simon R. Johnson, Rebecca Braybrooke, Guying Yu, Maor Sauler, Farida Ahangari, , Naftali Kaminski

A stabilized miR-29 mimic, MRG-229, shows efficacy at lower doses and good safety in preclinical models, supporting its development for pulmonary fibrosis.

EBioMedicine · Oct 17, 2022Peer-reviewedMolecular Biology

Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in In Vitro, In Vivo and Ex Vivo Models of Pulmonary Fibrosis

Farida Ahangari, Christine Becker, Daniel G. Foster, Maurizio Chioccioli, Meghan Nelson, K.M. Beke, Xing Wang, Benjamin P. Readhead, Carly Meador, Kelly A. Correll, Loukia N. Lili, Helen M. Roybal, Kadi-Ann Rose, Shuizi Ding, Thomas Bärnthaler, , Gregory Paul Downey

This study identifies saracatinib as a potential anti-fibrotic drug effective in multiple models of pulmonary fibrosis, showing equal or superior efficacy compared to existing treatments.

bioRxiv · Jan 4, 2022 · PreprintSystems Biology